Characteristics | Oral nonbiologic DMARD patients | MTX patients | Biologic DMARD patients |
---|---|---|---|
N = 1,698 | N = 1,217 | N = 3,263 | |
Demographics | |||
Age, mean (SD) | 49.8 (12.5) | 49.8 (12.3) | 49.4 (11.6) |
Female, number (%) | 927 (54.6) | 657 (54.0) | 1,736 (53.2) |
Combination of treatment with another nonbiologic DMARD and/or oral corticosteriod at the index date | 168 (9.9) | 138 (11.3) | 1,512 (46.3) |
During the 6-month pre-index period, including the index date | |||
Specialist encounter, number (%) | |||
Rheumatologist or Dermatologist | 1,175 (69.2) | 841 (12.3) | 2,347 (71.9) |
Rheumatologist | 1,055 (62.1) | 755 (62.0) | 2,008 (61.5) |
Dermatologist | 384 (22.6) | 271 (22.3) | 896 (27.5) |
During the 6-month pre-index period | |||
Comorbiditiesb,c, number (%) | |||
Hypertension | 364 (21.4) | 260 (21.4) | 670 (20.5) |
Diabetes | 175 (10.3) | 129 (10.6) | 376 (11.5) |
Hypothyroidism | 114 (6.7) | 81 (6.7) | 200 (6.1) |
Chronic pulmonary disease | 111 (6.5) | 72 (5.9) | 176 (5.4) |
Deficiency anemia | 77 (4.5) | 62 (5.1) | 164 (5.0) |
Psoriasis | 545 (32.1) | 420 (34.5) | 1,194 (36.6) |
Charlson comorbidity index, mean (SD) | 0.47 (0.87) | 0.44 (0.84) | 0.52 (0.88) |
Prior use of NSAID, oral corticosteriod, and nonbiologic DMARDs, number (%) | |||
NSAIDs | 991 (58.4) | 701 (57.6) | 1,665 (51.0) |
Oral corticosteriods | 550 (32.4) | 396 (32.5) | 1,036 (31.7) |
Nonbiologic DMARDs | 0 (0.0) | 0 (0.0) | 1,938 (59.4) |